<div class="infobox infobox-gene">
[@cdkal1_structure]
| Property | Value | [@thiolation_pathway]
|---------|-------| [@translation_fidelity]
| Gene Symbol | CDKAL1 |
| Full Name | CDK5 Regulatory Subunit Associated Protein 1-like 1 |
| Chromosomal Location | 5p13.3 |
| NCBI Gene ID | [54901](https://www.ncbi.nlm.nih.gov/gene/54901) |
| Ensembl ID | ENSG00000129625 |
| UniProt ID | [Q9Y5J9](https://www.uniprot.org/uniprot/Q9Y5J9) |
| Protein Length | 507 amino acids |
| Molecular Weight | 56.2 kDa |
</div>
CDKAL1 (CDK5 Regulatory Subunit Associated Protein 1-like 1) is a human gene encoding a highly conserved tRNA modification enzyme critical for cellular protein synthesis. The CDKAL1 protein is a member of the Cdk5 regulatory subunit-associated protein family, though its primary function is not related to CDK5 regulation. Instead, CDKAL1 catalyzes the 2-thiolation of cytidine at position 34 (s²C34) in specific tRNAs, a modification essential for translation accuracy and efficiency[@cdkal1_structure].
<div class="infobox infobox-gene">
[@cdkal1_structure]
| Property | Value | [@thiolation_pathway]
|---------|-------| [@translation_fidelity]
| Gene Symbol | CDKAL1 |
| Full Name | CDK5 Regulatory Subunit Associated Protein 1-like 1 |
| Chromosomal Location | 5p13.3 |
| NCBI Gene ID | [54901](https://www.ncbi.nlm.nih.gov/gene/54901) |
| Ensembl ID | ENSG00000129625 |
| UniProt ID | [Q9Y5J9](https://www.uniprot.org/uniprot/Q9Y5J9) |
| Protein Length | 507 amino acids |
| Molecular Weight | 56.2 kDa |
</div>
CDKAL1 (CDK5 Regulatory Subunit Associated Protein 1-like 1) is a human gene encoding a highly conserved tRNA modification enzyme critical for cellular protein synthesis. The CDKAL1 protein is a member of the Cdk5 regulatory subunit-associated protein family, though its primary function is not related to CDK5 regulation. Instead, CDKAL1 catalyzes the 2-thiolation of cytidine at position 34 (s²C34) in specific tRNAs, a modification essential for translation accuracy and efficiency[@cdkal1_structure].
Located at chromosome 5p13.3, the CDKAL1 gene encodes a 507-amino acid protein that belongs to the THiS family of tRNA modification enzymes. The enzyme requires a [4Fe-4S] iron-sulfur cluster for catalytic activity, linking its function to cellular iron metabolism. CDKAL1's role in tRNA modification has significant implications for protein synthesis fidelity, which is particularly important in metabolically active cells like neurons that require precise proteostasis.
Originally identified through genome-wide association studies (GWAS) as a significant risk locus for type 2 diabetes mellitus, CDKAL1 has since attracted attention in the neuroscience community due to emerging evidence linking tRNA modifications to neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS) [@diabetes_cdkal1].
CDKAL1 catalyzes the addition of a sulfur atom to the 2-position of cytidine at position 34 in tRNA. This position is the "wobble" position of the anticodon, which plays a critical role in codon-anticodon pairing during translation[@thiolation_pathway].
The 2-thiolation modification (s²C) occurs primarily on tRNA species that recognize codons ending in G. These include:
CDKAL1 requires iron-sulfur cluster cofactors for catalytic activity. The enzyme uses a sulfur relay system involving:
CDKAL1 shows substrate specificity for specific tRNA species based on their anticodon sequences. The enzyme primarily modifies tRNAs with uridine at the first anticodon position (position 34) that recognize codons ending in purines (A or G).
The target tRNAs include those encoding lysine, glutamine, glutamate, and arginine. These amino acids are encoded by multiple codons, and the s²C modification improves decoding efficiency at specific codon families.
CDKAL1-mediated tRNA thiolation is essential for maintaining translation fidelity. Without s²C modification, the wobble interaction between tRNA and codon is weakened, leading to[@translation_fidelity]:
The s²C modification specifically prevents ribosome stalling at proline-rich sequences. Proline is unique among amino acids because its secondary amine backbone cannot form the typical hydrogen bonds that stabilize the peptide bond. This causes ribosomes to pause at polyproline sequences[@ribosome_stalling].
The s²C modification on tRNA^Arg(UCU) and other tRNAs facilitates the incorporation of proline by improving codon recognition and preventing ribosome stalling. CDKAL1 deficiency leads to ribosomal accumulation at polyproline sequences, reducing translation efficiency.
CDKAL1 is highly expressed in neurons, particularly at synapses, where local protein synthesis is essential for synaptic plasticity. The enzyme is required for synthesizing synaptic proteins that contain proline-rich domains, including[@synaptic_proteins]:
CDKAL1 is expressed throughout the brain, with highest levels in the hippocampus, cortex, and cerebellum. In neurons, CDKAL1 localizes to both the soma and dendritic compartments, including dendritic spines.
Neuronal CDKAL1 expression is activity-dependent. Synaptic activity upregulates CDKAL1 levels, suggesting it responds to functional demands for protein synthesis. This regulation may be important for synaptic plasticity and memory consolidation.
While primarily a neuronal protein, CDKAL1 is also expressed in astrocytes and microglia. In these glial cells, CDKAL1 may support the high metabolic demands of glial function, including neurotransmitter recycling and immune modulation.
The most well-established disease association of CDKAL1 is with type 2 diabetes mellitus (T2DM). Multiple GWAS studies have identified variants in the CDKAL1 gene region as significant determinants of T2DM risk[@diabetes_cdkal1]. The mechanism involves impaired β-cell function:
In [Alzheimer's disease](/diseases/alzheimers-disease), several tRNA modifications are altered, including s²C modification by CDKAL1. Studies show reduced CDKAL1 expression in AD brains[@alzheimer_trna], which may contribute to the translation deficits observed in AD neurons.
The loss of CDKAL1 function in AD may result from:
Human genetic studies link CDKAL1 variants to cognitive function. While most research has focused on CDKAL1's role in diabetes, variants associated with diabetes risk also show associations with cognitive performance in non-diabetic populations[@cognitive_function].
In [Parkinson's disease](/diseases/parkinsons-disease), mitochondrial dysfunction is a central pathogenic feature. Mitochondrial tRNA modifications are particularly important because mitochondrial translation is essential for assembling the electron transport chain[@mitochondrial_trna].
CDKAL1 is primarily a cytoplasmic enzyme, but related tRNA modification pathways operate in mitochondria. Disruption of mitochondrial tRNA modifications in PD may contribute to the electron transport chain deficits that characterize dopaminergic neuron vulnerability.
PD involves significant oxidative stress, generated by dopamine metabolism and mitochondrial dysfunction. Oxidative stress impairs CDKAL1 function by[@oxidative_stress]:
Dopaminergic neurons in the substantia nigra are particularly vulnerable to stressors. The high metabolic demands of these neurons require efficient protein synthesis and quality control. CDKAL1 deficiency may make dopaminergic neurons more vulnerable to the specific stressors relevant to PD pathogenesis.
ALS research has begun to implicate tRNA modification pathways:
The common thread linking CDKAL1 to multiple neurodegenerative diseases is its essential role in maintaining translational fidelity, particularly in mitochondria-rich cells like neurons and pancreatic β-cells. Key shared mechanisms include:
CDKAL1 represents a potential therapeutic target for neurodegenerative diseases. Strategies include[@therapeutic_target]:
CDKAL1 function is closely linked to selenoprotein synthesis because selenocysteine incorporation requires specific tRNA modifications similar to s²C. The selenium pathway may influence CDKAL1 function indirectly[@selenium_metabolism].
Because CDKAL1 requires iron-sulfur clusters for activity, maintaining proper iron homeostasis may support CDKAL1 function. Iron dysregulation is a feature of both AD and PD, making this an attractive therapeutic angle.
Key unanswered questions about CDKAL1 in neurodegeneration include: